by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
by Truveta staff | Nov 21, 2023 | Data
ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different audiences view current challenges and opportunities related to real-world data (RWD). Here...
by Terry Myerson, CEO | Nov 20, 2023 | Culture
Eight months ago, we had a fateful meeting… “We have some incredibly diverse and engaged customers doing innovative work that would benefit from meeting and learning from each other…. Our solutions are getting more powerful, and we want to get the word out… We want to...
by Truveta staff | Nov 16, 2023 | Data
In the world of healthcare, few conditions have seen as much transformation over the past decade as diabetes. With 37.3 million Americans living with diabetes, and a further 96 million in the prediabetes stage, it’s a life-altering health concern for nearly 40% of the...
by Truveta Research | Nov 10, 2023 | Research, Research Insights
Adequate treatments are a crucial piece in the fight against the spread of HIV, because they can make HIV viral load undetectable in the blood and thus untransmittable. Approved by the US Food and Drug Administration (FDA) in January 2021, one of the newest treatments...
by Truveta Research | Nov 10, 2023 | Research, Research Insights
Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
by Truveta staff | Nov 8, 2023 | Data, News, Technology
When I had the first conversations about creating Truveta, I knew technology was the answer to solving healthcare data challenges. Healthcare data traditionally has been too siloed, inaccessible, and messy to be useful for research. And one of the biggest challenges...
by Truveta Research | Nov 2, 2023 | Research, Research Insights
Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
by Truveta staff | Nov 1, 2023 | Data
October was a whirlwind month for Truveta, marked by participation in various conferences across the United States. In the span of less than 10 days, Truveta experts and customers presented at four different events, showcasing how Truveta Data is being used to enable...
